

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

**Complete If Known**

Application Number	10/556,229
Filing Date	November 9, 2005
First Named Inventor	Yevgeni BESIDSKI
Art Unit	Not Known
Examiner Name	Not Known
Attorney Docket Number	101062-1P US

Sheet	1	of	4
-------	---	----	---

## U. S. PATENT DOCUMENTS

[illegible]

## FOREIGN PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T <sup>2</sup>
		Country Code <sup>3</sup> Number <sup>4</sup> Kind Code <sup>5</sup> (if known)	MM-DD-YYYY			
/GS/	A4	WO 03/049702	06-19-2003	Amgen Inc.		
	A5	WO 04/024154 A1	03-25-2004	Glaxo Grp Limited		
	A6	WO 99/00115	01-07-1999	Smithkline Beecham PLC		
	A7	WO 03/014064 A1	02-20-2003	Bayer Aktiengesellschaft		
	A8	WO 02/50031 A1	06-27-2002	Glaxo Grp Limited		
	A9	WO 01/12189 A1	02-22-2001	Pharmacia & Upjohn S.P.A.		

Examiner Signature	/Golam Shameem/	Date Considered	11/20/2007
-----------------------	-----------------	--------------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

**If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.**

Substitute for form 1449/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet

2

1

4

---

Attorney Docket Number

101062-1P US

**Complete if Known**

Application Number

10/556.229

Filing Date

November 9, 2005

First Named Inventor

**Yevgeni BESIDSKI**

**Art Unit**

Not Known
-----------

Examiner Name
---------------

Not Known
-----------


Attorney Docket Number

101062-1P US

## U. S. PATENT DOCUMENTS

[illegible]

## FOREIGN PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T <sup>2</sup>
		Country Code <sup>3</sup> Number <sup>4</sup> Kind Code <sup>5</sup> (if known)				
	A10	WO 94/22859	10-13-1994	Bayer Aktiengesellschaft		
	A11	WO 04/000828 A1	12-31-2003	Biovitrum AB		
	A12	WO 02/100822 A1	12-19-2002	Biovitrum AB		
	A13	WO 01/96336 A2	12-20-2001	Warner-Lambert Co		
	A14	WO 01/85722 A1	11-15-2001	Cor Therapeutics, Inc.		
	A15	GB 1,186,504	04-02-1970	Fisons Pest Control Lmt'd		

**Examiner  
Signature**

/Golam Shameem/

Date  
Considered

11/20/2007

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

**If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.**

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

**(Use as many sheets as necessary)**

Sheet 1

3

of

4

**Complete if Known**

Application Number	10/556,229
--------------------	------------

Filing Date	November 9, 2005
-------------	------------------

First Named Inventor	Yevgeni BESIDSKI
----------------------	------------------

Art Unit	Not Known
----------	-----------

Examiner Name	Not Known
---------------	-----------

Attorney Docket Number	101062-1P US
------------------------	--------------

## U. S. PATENT DOCUMENTS

[illegible]

## FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	† <sup>6</sup>
		Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)	MM-DD-YYYY			
/GS/	A16	WO 03/068749 A1	08-21-2003	Glaxo Group Limited		
↓	A17	WO 04/024710	03-25-2004	Glaxo Group Limited		
	A18	WO 03/022809 A2	03-20-2003	SmithKline Beecham PLC		
	A19	WO 03/053945 A2	07-03-2003	SmithKline Beecham PLC		
	A20	WO 02/090326 A1	11-14-2002	SmithKline Beecham PLC		
	A21	WO 02/072536 A1	09-19-2002	SmithKline Beecham PLC		

**Examiner  
Signature**

/Golam Shameem/

Date  
Considered

11/20/2007

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

**If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.**

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO		<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>(Use as many sheets as necessary)</i>		Application Number	10/556,229
		Filing Date	November 9, 2005
		First Named Inventor	Yevgeni BESIDSKI
		Art Unit	Not Known
		Examiner Name	Not Known
Sheet <u>4</u> of <u>4</u>	Attorney Docket Number	101062-1P US	

U. S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code <sup>2</sup> (if known)			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T <sup>4</sup>
		Country Code <sup>3</sup> Number <sup>4</sup> Kind Code <sup>5</sup> (if known)				
/GS/	A22	EP 1 312 601 A1	05-21-2003	Ono Pharmaceutical Co		
	A23	EP 0 419 210 A1	03-27-1991	Pfizer Inc		
	A24	EP 0 149 200	12-20-1984	Dr. Karl Thomae GmbH		

Examiner Signature	/Golam Shameem/	Date Considered	11/20/2007
-----------------------	-----------------	--------------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

**Complete if Known**

Application Number	10/556,229
Filing Date	11/09/2005
First Named Inventor	Yevgeni Besidski
Art Unit	Not
Examiner Name	Not Known
Attorney Docket Number	101062-1P US

Sheet 1 of 4

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
/GS/ ↓	A25	MCDONNELL, et al., "7-Hydroxynaphthalen-1-yl-Urea and -Amide Antagonists of Human Vanilloid Receptor 1"; Bioorganic & Medicinal Chemistry Letters 14 (2004), pgs 531-534	
	A26	MUSSO, et al., "Indanylidenes. 1. Design and Synthesis of . . . and Analgesic Activity"; J. Med. Chem 2003, 46, pgs 399-408	
	A27	YIANGOU, et al., "Capsaicin Receptor VR1 and ATP-Gated ion Channel P2X3, in Human Urinary Bladder"; BJU International (2001), 87, pgs 774-779	
	A28	WALKER, et al., "The VR1 Antagonist Capsazepine . . . Inflammatory and Neuropathic Pain"; J. Pharmacology & Experimental Therapeutics, Vol. 304, No. 1, pgs 56-62	
	A29	RASHID, et al., "Novel Expression of Vanilloid . . . in Neuropathic Pain"; J. Pharmacology & Experimental Therapeutics, vol 304, No. 3, pgs 940-948	
	A30	CATERINA, et al., "The Capsaicin Receptor: A Heat-Activated Ion Channel in the Pain Pathway"; Nature, Vol 389, Oct 23, 1997, pgs 816-824	
	A31	TOMINAGA, et al., "The Cloned Capsaicin Receptor Integrates Multiple Pain-Producing Stimuli"; Neuron, Vol 21, September 1998, pgs 531-543	
	A32	HWANG, et al., "Hot Channels in Airways: Pharmacology of the Vanilloid Receptor"; Respiratory, Curr Opin Pharmacol 2002, June, 2(3) pgs 235-242	
	A33	SZALLASI, et al. "Vanilloid (Capsaicin) Receptors in Health and Disease"; Am J Clin Pathol 2002, 118, pgs 110-121	
	A34	T.L. GILCHRIST, "Heterocyclic Chemistry", 2nd Edition, Longman Scientific and Technical (1992), pgs 248-282	

Examiner  
Signature

/Golam Shameem/

Date  
Considered

11/20/2007

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet

2

of

4

**Complete if Known**

Application Number	10/556,229
Filing Date	11/09/2005
First Named Inventor	Yevgeni Besidski
Art Unit	Not
Examiner Name	Not Known
Attorney Docket Number	101062-1P US

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS); title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
/GS/	A35	B. Bijaya Kumar, V. Malla Reddy, Indian Journal of Chemistry, Vol 24B, Oct 1985, pgs 1098-1101, Table 1, Scheme I	
	A36	Anthony Gallard, et al., Journal of Enzyme Inhibition and Medicinal Chemistry, Vol 18, No. 2. 2003, "New N-Pyridinyl(methyl)-N1-Substituted . . . Systemic anti-Inflammatory Agents", pgs 201-208	
	A37	STN International, Accession No. 200:912544, 24 April 2003, CHS 0297096, "1H-Benzimidazole-1-acetamide, N-[3-(trifluoromethyl)phenyl]-CAS Registry No. 294669-15-1	
	A38	STN International, Accession No. 2000:532079, 23 april 2003, BAS 0238979, "1H-Benzimidazole-1-acetamide, N-(3-chlorophenyl)-CAS Registry No. 116488-26-7	
	A39	STN International, Accession No. 2001:10738, 24 April 2003, NS11937, "1H-Indole-3-butanamide, N-(4-methylphenyl)-CAS Registry No. 313550-48-0	
	A40	STN International, Accession No. 2001:1505160, 29 April 2003, AG-690/40696518, "1H-Benzimidazole-1-acetamide,N-(2,3-dichlorophenyl)-, CAS Registry No. 332384-60-8	
	A41	STN International, Accession No. 2002:2035573, 09 July 2002, ASN 1816063, "1H-Benzimidazole-1-acetamide,N-(3-chloro-4-methylphenyl)" -CAS Registry No. 332908-87-9	
	A42	STN International, Accession No. 2002:2042451, 09 July 2002, ASN 4428244, "1H-Benzimidazole-1-acetamide,N-(5-amino-2-methylphenyl)" - CAS registry No. 436095-70-4	
	A43	STN International, Accession No. 2003:454497, 30 April 2003, ASN 5212034, "1H-Indole-3-acetamide, N-[4-(1-methylethyl)phenyl]" - CAS Registry No. 460336-68-9	
	A44	STN International, Accession No. 2003:454500, 30 april 2003, ASN 5212038, 1H-Indole-3-acetamide, N-(3,5-dimethoxyphenyl)" - CAS Registry No. 460336-71-4	

Examiner  
Signature

/Golam Shameem/

Date  
Considered

11/20/2007

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)		<b>Complete if Known</b>			
		Application Number	10/556,229		
		Filing Date	11/09/2005		
		First Named Inventor	Yevgeni Besidski		
		Art Unit	Not		
		Examiner Name	Not Known		
Sheet	3	of	4	Attorney Docket Number	101062-1P US

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
/GS/	A45	STN International, Accession No. 2003:1778448, 09 July 2002, ASN 3067491, "1H-Benzimidazole-1-acetamide, N-(2-fluorophenyl)" - CAS Registry No. 483326-88-1	
	A46	STN International, Accession No. 2003:1780032, 09 July 2002, ASN 3110045, "1H-Benzimidazole-1-acetamide, 5,6-dimethyl-N-[2-(trifluoromethyl)phenyl]" - CAS Registry No. 483347-09-7	
	A47	STN International, Accession No. 2003:1780036, 09 July 2002, ASN 3110053, "1H-Benzimidazole-1-acetamide, N-(2,4-dimethoxyphenyl)-5,6-dimethyl" - CAS Registry No. 483347-12-2	
	A48	STN International, Accession No. 2003:1780041, 09 July 2002, ASN 3110088, "1H-Benzimidazole-1-acetamide, N-[4-(dimethylamino)phenyl]-5,6-dimethyl" - CAS Registry No. 483347-17-7	
	A49	STN International, Accession No. 2003:1783073, 09 July 2002, ASN 3212475, "1H-Benzimidazole-1-acetamide, N-(3-fluorophenyl)" - CAS Registry No. 483978-05-8	
	A50	STN International, Accession No. 2003:2842871, 30 April 2003, BAS 5595011, "1H-Indole-3-acetamide, N-(3-fluoro-4-methylphenyl)" - CAS Registry No. 510764-85-9	
	A51	STN International, Accession No. 2003:3562090, 30 April 2003, ZT-5586656, "1H-Indole-3-propanamide, N-[2-(1-methylethyl)phenyl]" - CAS Registry No. 556791-23-2	
	A52	STN International, Accession No. 2003:3425665, 30 April 2003, ZT-2132403, "1H-Indole-3-propanamide, N-[4-(1,1-dimethylethyl)phenyl]" - CAS Registry No. 562052-38-4	
	A53	STN International, Accession No. 2003:3428083, 30 April 2003, ZT-2150185, "1H-Indole-3-propanamide, N-(2-chloro-4-methylphenyl)" - CAS Registry No. 562794-00-7	
	A54	STN International, Accession No. 2002:737351, document no. 138:265138, Olgen, Sureyya, et al., "Synthesis and . . . indole-3-acetamide derivatives", & Archiv der Pharmazie (Weinheim, Germany) (2002), 335(7), 331-338	

Examiner Signature	/Golam Shameem/	Date Considered	11/20/2007
--------------------	-----------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)		Application Number	10/556,229
		Filing Date	11/09/2005
		First Named Inventor	Yevgeni Besidski
		Art Unit	Not
		Examiner Name	Not Known
		Attorney Docket Number	101062-1P US
Sheet	4	of	4

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
/GS/	A55	STN International, Accession No. 2002:695939, document n o. 137:232452, Rotta Research Lab, S.p.A., "Preparation of benzamidines having antiinflammatory & immunosuppressive activity", & WO2002070468,A2,20020912	
	A56	STN International, Accession No. 2000:825244, document no. 134:147129, Jamieson, Craig, et al., "A rapid approach for the optimization of polymer supported reagents in synthesis", & Synlett (2000), (11), 1603-1607	
	A57	STN International, Accession No. 1988:610992, document no. 109:210992, Shah, V.H., et al., "Studies on acetamide derivatives. Part-II. Preparation . . . sulfamethazin-4-y/acetamides", & Jr of the Indian Chemical Society (1987), 64(11), 678-81	
	A58	STN International, Accession No. 1958:31856, document n o. 52:31856, Cacace, Fulvio, et al., "Benzimidazole-N-acetic . . . growth activity", & Atti accad. nazl. Lincei. Rend., Classe sci. fiz., mat. e nat. (1957), 22, 510-13	
	A59	STN International, Accession No. 1993:102385, document no. 118:102385, Gallant, Michel, et al., "A stereoselective synthesis . . . of rebeccamycin", & Jr of Organic Chemistry (1993), 58(2), 343-9	
	A60	STN International, Accession No. 1998:227318, document no. 128:308402, Sanwa Kagaku Kenkyusho Co., Ltd., "Preparation of . . . as antiarteriosclerotics", & JP, A2, 10095766, 19980414	
	A61	STN International, Accession No. 1995:594439, document no. 123:9266, Interneuron Pharm, Inc., "Substituted tryptamines . . . and related compounds", & US,A,5403851,19950404	
	A62	International Search Report for International Application No.PCT/SE2004/000738	
	A63	International-Type Search Report	

Examiner Signature	/Golam Shameem/	Date Considered	11/20/2007
--------------------	-----------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.